Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock

Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference

Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Chairman and CEO Robert Ward to Participate in a Panel Discussion at the Biotech Showcase 2018 Conference